Hypoglycemia Unawareness in Insulinoma Revealed with Flash Glucose Monitoring Systems

Overview

Journal Intern Med

Specialty General Medicine

Date 2018 Aug 14

PMID 30101920

Citations 13

Authors

Taku Sugawa

Takaaki Murakami

Daisuke Yabe

Riko Kashima

Makiko Tatsumi

Shinobu Ooshima

Erina Joo

Keiko Wada

Atsushi Yoshizawa

Toshihiko Masui

Yuji Nakamoto

Yuki Yamauchi

Yuzo Kodama

Yoshiki Iemura

Masahito Ogura

Akihiro Yasoda

Nobuya Inagaki

Affiliations

Soon will be listed here.

Abstract

The delayed diagnosis of insulinoma remains a clinical issue. One of the main causes of such a delay is hypoglycemia unawareness. A 53-year-old woman fell unconscious during postprandial exercises. Flash glucose monitoring (FGM) systems revealed glucose profiles with fasting hypoglycemia, which facilitated the clinical diagnosis of insulinoma even though she was unaware of her hypoglycemia. The preoperative comparison of the blood glucose values provided by FGM with those obtained from capillary blood were consistent. Thus, FGM may have potential utility in revealing the presence of insulinoma-induced hypoglycemia.

Citing Articles

Hypovascular insulinoma with reduced microvessel density on histopathology: a case report.

Imai R, Sakai M, Kato T, Ozeki S, Kubota S, Liu Y Diabetol Int. 2024; 15(4):855-860.

PMID: 39469562 PMC: 11512940. DOI: 10.1007/s13340-024-00756-z.

Insulinoma Unmasked: A Continuous Glucose Monitoring-Fueled Journey.

Koceva A, Krajnc M Curr Oncol. 2024; 31(9):5452-5461.

PMID: 39330031 PMC: 11431697. DOI: 10.3390/curroncol31090403.

A Case Report: Hypoglycaemic Unawareness Associated With Insulinoma.

Alkundi A, Momoh R Cureus. 2024; 16(7):e64994.

PMID: 39161528 PMC: 11332653. DOI: 10.7759/cureus.64994.

A case of insulinoma misidentified as schizophrenia due to its manifestation in neuropsychiatric symptoms.

Haba T, Yamakawa K, Ozeki S, Sumida A, Kato T, Kuroda E Diabetol Int. 2024; 15(3):611-615.

PMID: 39101165 PMC: 11291769. DOI: 10.1007/s13340-024-00722-9.

Insulinoma with Hyperprocalcitoninemia and Hypercalcitoninemia Showing Coexpression of Insulin and Calcitonin in Its Tumor Cells.

Kaketaka T, Mineo I, Kimura Y, Ito N, Okauchi Y, Tamura H Intern Med. 2023; 63(10):1415-1420.

PMID: 37839887 PMC: 11157324. DOI: 10.2169/internalmedicine.1565-23.

References

Dizon A, Kowalyk S, Hoogwerf B . Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999; 106(3):307-10. DOI: 10.1016/s0002-9343(99)00021-2. View

Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini J, Richard B . Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab. 2003; 88(11):5353-60. DOI: 10.1210/jc.2002-021895. View

Graves T, Gandhi S, Smith S, Sisodiya S, Conway G . Misdiagnosis of seizures: insulinoma presenting as adult-onset seizure disorder. J Neurol Neurosurg Psychiatry. 2004; 75(8):1091-2. PMC: 1739168. DOI: 10.1136/jnnp.2003.029249. View

Service F, McMahon M, OBrien P, Ballard D . Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991; 66(7):711-9. DOI: 10.1016/s0025-6196(12)62083-7. View

Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J . Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol (Oxf). 2007; 68(6):912-8. DOI: 10.1111/j.1365-2265.2007.03161.x. View

Placzkowski K, Vella A, Thompson G, Grant C, Reading C, Charboneau J . Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab. 2009; 94(4):1069-73. DOI: 10.1210/jc.2008-2031. View

Poeppel T, Binse I, Petersenn S, Lahner H, Schott M, Antoch G . 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011; 52(12):1864-70. DOI: 10.2967/jnumed.111.091165. View

Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K . Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2014; 50(1):58-64. DOI: 10.1007/s00535-014-0934-2. View

Sharma P, Arora S, Karunanithi S, Khadgawat R, Durgapal P, Sharma R . Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma. Q J Nucl Med Mol Imaging. 2014; 60(1):69-76. View

10.

Imamura M, Nakamoto Y, Uose S, Komoto I, Awane M, Taki Y . Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2015; 22(8):602-9. DOI: 10.1002/jhbp.209. View

11.

Bailey T, Bode B, Christiansen M, Klaff L, Alva S . The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technol Ther. 2015; 17(11):787-94. PMC: 4649725. DOI: 10.1089/dia.2014.0378. View

12.

Rokutan M, Yabe D, Komoto I, Kurose T, Kawai J, Nakamura T . A case of insulinoma with non-alcoholic fatty liver disease: Roles of hyperphagia and hyperinsulinemia in pathogenesis of the disease. Endocr J. 2015; 62(11):1025-30. DOI: 10.1507/endocrj.EJ14-0590. View

13.

Heinemann L, Freckmann G . CGM Versus FGM; or, Continuous Glucose Monitoring Is Not Flash Glucose Monitoring. J Diabetes Sci Technol. 2015; 9(5):947-50. PMC: 4667350. DOI: 10.1177/1932296815603528. View

14.

Nakamoto Y, Ishimori T, Sano K, Temma T, Ueda M, Saji H . Clinical efficacy of dual-phase scanning using (68)Ga-DOTATOC-PET/CT in the detection of neuroendocrine tumours. Clin Radiol. 2016; 71(10):1069.e1-1069.e5. DOI: 10.1016/j.crad.2016.04.017. View

15.

Van Beers C, DeVries J, Kleijer S, Smits M, Geelhoed-Duijvestijn P, Kramer M . Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016; 4(11):893-902. DOI: 10.1016/S2213-8587(16)30193-0. View

16.

Nockel P, Babic B, Millo C, Herscovitch P, Patel D, Nilubol N . Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan. J Clin Endocrinol Metab. 2016; 102(1):195-199. PMC: 6083884. DOI: 10.1210/jc.2016-3445. View

17.

Aberer F, Hajnsek M, Rumpler M, Zenz S, Baumann P, Elsayed H . Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes. Diabetes Obes Metab. 2017; 19(7):1051-1055. DOI: 10.1111/dom.12907. View

18.

Fokkert M, van Dijk P, Edens M, Abbes S, de Jong D, Slingerland R . Performance of the FreeStyle Libre Flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2017; 5(1):e000320. PMC: 5316912. DOI: 10.1136/bmjdrc-2016-000320. View

19.

Murakami T, Usui T, Nakamoto Y, Nakajima A, Mochida Y, Saito S . Challenging Differential Diagnosis of Hypergastremia and Hyperglucagonemia with Chronic Renal Failure: Report of a Case with Multiple Endocrine Neoplasia Type 1. Intern Med. 2017; 56(11):1375-1381. PMC: 5498202. DOI: 10.2169/internalmedicine.56.7230. View

20.

Sekido K, Sekido T, Kaneko A, Hosokawa M, Sato A, Sato Y . Careful readings for a flash glucose monitoring system in nondiabetic Japanese subjects: individual differences and discrepancy in glucose concentrarion after glucose loading [Rapid Communication]. Endocr J. 2017; 64(8):827-832. DOI: 10.1507/endocrj.EJ17-0193. View